Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I actually got the impression from you that phase 1 was not what we were waiting for but phase 2 where the bigger money was. That's why I have been looking to see if horizon 2020 recipients for phase 2 have been released yet. What other horizon 2020 grant are you referring to?
Then you get to gloat?
There were over 1000 applicants for phase 1. The only place their name shows up is if they received phase 1. I wouldn't expect you to see mantra listed on the horizon 2020 website, unless this week they announce the recipients for phase 2 and mantra gets a grant.
From this article about the horizon 2020 phase 1 recipients, it appears they'll make announcements about phase 2 recipients in "mid November."
http://wsstp.eu/news/141-highly-innovative-smes-get-funded-under-phase-1-of-the-horizon-2020-sme-instrument/
And by the way, my comments have nothing to do with any agenda regarding stocks or making money in general. I'm a elementary educator, have a degree in environmental science, and am simply sharing my thoughts based on my own truth and justice. Good luck to you as well.
I bet you do.
Unlike all the other topics I read and surmise about on this board, I'm feeling pretty confident in my education and knowledge about this topic. Thanks.
I'm going to respectfully say that is ignorant to ignore the abundant data and the most respected scientists and scientific communities- not to mention more recent temperature and other data from the last 20 years-which all affirm that humans have and are affecting the presence and effects of greenhouse gasses. Yes, the science is complex, but come on, man. Turn of fox.
Me too. ??
Why the 17th?
RXi Pharmaceuticals Gets Postive Review for Scar Revision Treatment - Shares Jumping 16% Pre-Market
10/15/15, 7:09 AM
07:09 AM EDT, 10/15/2015 (MT Newswires) -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, said results from a blinded panel and an investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.
It seems like more MMs want this to run. A month ago, NSDQ was the only one controlling the action- that's definitely changed lately...
Been following for a couple of months- why haven't I invested more?
This is a lot of fun to watch!!!
An additional 20,000 showed up in the volume after the market closed, and while the closing price stayed the same (in my td ameritrade app) the graph showed it closed below .07. That coincides with the post about the after hours trade, so it seems to have happened. My 2¢
His response was earlier in the day, and then there were 20000 traded after the close to drop it more...
Or not.
"Some news out this morning that should help the share price recover from Friday"
Optex Systems, Inc. Announces $850,000 Settlement Agreement on Aiming Circle Contract
9/28/15, 6:00 AM
RICHARDSON, TX -- (Marketwired) -- 09/28/15 -- Optex Systems, Inc., a wholly owned subsidiary of Optex Systems Holdings, Inc. (OTCQB: OPXS), a leading manufacturer of optical sighting systems and assemblies for domestic and foreign militaries, announced today that the U.S. Government has agreed to a $850,000 settlement on Optex's request for equitable adjustment on the Aiming Circle contract number W52H09-06-D-0229 in which shipments concluded in 2011. This settlement is the result of a negotiation and fact gathering process managed through the Armed Services Contract Board of Appeals (ASBCA).
"This settlement signifies a significant effort put forth by the technical and business teams here at Optex and at the U.S. Army's Tank-automotive & Armaments Command (TACOM). We appreciate the efforts of all involved including the significant time invested by the TACOM personnel to reach this conclusion," stated Danny Schoening, Optex's CEO. He continued, "While a request for an equitable adjustment is not the desired path by either party, we appreciate the methodology afforded to small businesses through the ASBCA office in the rare occasion that it is needed."
ABOUT OPTEX SYSTEMS
Optex, which was founded in 1987, is a Richardson, Texas based ISO 9001:2008 certified concern, which manufactures optical sighting systems and assemblies, primarily for Department of Defense (DOD) applications. Its products are installed on various types of U.S. military land vehicles, such as the Abrams and Bradley fighting vehicles, Light Armored and Armored Security Vehicles, and have been selected for installation on the Stryker family of vehicles. Optex also manufactures and delivers numerous periscope configurations, rifle and surveillance sights and night vision optical assemblies. Optex delivers its products both directly to the military services and to prime contractors. For additional information, please visit the Company's website at www.optexsys.com.
Safe Harbor Statement
This press release and other written reports and oral statements made from time to time by the Company may contain so-called "forward-looking statements," all of which are subject to risks and uncertainties. You can identify these forward-looking statements by their use of words such as "expects," "plans," "will," "estimates," "forecasts," "projects" and other words of similar meaning. You can identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company's growth strategy, financial results and product and development programs. You must carefully consider any such statement and should understand that many factors could cause actual results to differ from the Company's forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. You should carefully evaluate such statements in light of factors described in the Company's filings with the SEC, especially on Forms 10-K, 10-Q and 8-K. In various filings the Company has identified important factors that could cause actual results to differ from expected or historic results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete list of all potential risks or uncertainties.
Contact:Optex Systems Holdings, Inc. Stan HirschmanPresident (972) 764-5677ir@optexsys.com 1420 Presidential Drive Richardson, TX 75081
Source: Optex Systems Holdings, Inc.
I saw that too- it's the first time I've heard clearly which phase we were / are in with Alstom. I think that was the only positive thing I read in the whole document. Oi.
Here's a link to a similar thing filed 1 year ago:
http://www.otcmarkets.com/stock/MVTG/news?id=88064&b=y
Looks like it was reinstated after they filed their form. Seems to be an annual thing when they're late.
Actually he was helping me understand that fact. Ty.
Mantra's investor presentation describes their MRFC and shows the picture of the Swiss roll inside. Nowhere do they say there is any other kind of MRFC. I believe they decided to drop the phrase Swiss Roll. It's one and the same. Unless, once again, you provide me a link to show otherwise. The posts you reference definitely don't resolve this question.
I guess I'm interpreting things differently. That's why I asked for a link where mantra's mixed reactant fuel cell is shown to be different than the Swiss roll. The Swiss roll was what made a MRFC possible- so I thought...
Can you send me a link to that information? Thanks.
The journals in the post you mention only talk about the SR-MRFC. I can't find anything on their website that says the MRFC is different than the SR. Can anyone direct me to a source other than a comment on ihub? Only recently has it been suggested that one is different than the other. The mention from 2015 about only borohydride being used was true back then- but if the spark uses formate and the MRFC is actually the SR-MRFC, then advancements have been made since then, no?
Is sodium borohydride the same as formate salts?
I just checked mantras website- they show the MRFC with the Swiss roll inside, but just refer to it as the MRFC. Plus, "While the MRFC can produce power from many different fuels, the Spark is powered by formate salts," said Mantra's CTO SonaKazemi.
So the MRFC is the SR-MRFC? And if it's running on formic acid, that would suggest further developments have occurred since the journal articles were written in 2014.
I'm still unclear regarding whether the MRFC includes the Swiss roll architecture. From what I've read, it seems the Swiss roll is what makes the MRFC possible. In the journals cited it refers to the SR-MRFC- everywhere else just MRFC.
Forgive my ignorance, but isn't it the Swiss roll that makes the MRFC possible? Didn't they do that with the spark?
I'd like to second this post.
That's weird. The date at the top says August 31, 2015, but the text is clearly written when mvtg hit .67 early last year. Bizarro
I also notice Daniel Guay on the schedule...
from October 28, 2014...
Vancouver, British Columbia– Mantra Venture Group Ltd. (OTCQB: MVTG) and its subsidiary, Mantra Energy Alternatives Ltd., have announced the successful award of a NSERC Strategic Project Grant along with their collaborator, Professor Daniel Guay of the Institut national de la recherche scientifique (INRS). Through the grant, NSERC will provide approximately $450,000 of funding for the three-year research collaboration, which will develop the electro-reduction of CO2 (ERC) process...
And pft...
This is an interest start to the week...
So even the shorts are losing interest? :)
Did something change to cause you to be more optimistic? I've noticed you seem to be more positive lately. Did you buy more at these low levels?
In true Eco form. Well?!?!?!
6/9/15, 7:02 AM
MARLBOROUGH, Mass., June 9, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi's novel, self-delivering RNAi platform (sd-rxRNA®). The patent, titled "Reduced Size Self-Delivering RNAi Compounds," covers both the composition and methods of use of RXi's self-delivering platform. The patent, once issued, will be scheduled to expire in 2031.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Importantly, this patent expands the scope of RXi's self-delivering RNAi platform with the incorporation of novel oligonucleotide chemical modifications. These chemical modifications result in improved biodistribution following systemic administration and may be beneficial for local delivery applications in the central nervous system.
In addition, RXi announced that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi's rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be scheduled to expire in 2029.
"We are pleased to receive both of these Notices of Allowance from the USPTO, which further broaden and protect the Company's already robust patent estate." said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He further added, "RXi's intellectual property portfolio is a highly valuable corporate asset that provides substantial protection for our novel technology platform and offers numerous product and business development opportunities."
07:57 AM EDT, 06/08/2015 (MT Newswires) -- Advaxis (ADXS), a biotechnology company, said preliminary data demonstrate that its ADXS-HER2, in combination with palliative radiation, delayed tumor progression and prolonged overall survival in a group of 12 pet dogs with treatment naive spontaneous osteosarcoma.
The company said repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity.
Of the 12 canine patients recruited to date, seven are alive with survival times ranging from 66 to 479 days. The median survival time of dogs receiving palliative radiation plus ADXS-HER2 has not been reached. The median time to progression of the 12 canine patients is 238 days. The reported median survival time for historical control dogs with OSA that do not undergo amputation but instead receive the same palliative radiation protocol without ADXS-HER2 is 136 days.
ADXS licensed ADXS-HER2 to Aratana Therapeutics (PETX) in March of 2014 for pet health indications and it is now being developed and prepared for commercialization using the name AT-014. ADXS and PETX anticipate conditional licensure of AT-014 for the treatment of canine OSA from the U.S. Department of Agriculture in 2016.